title: Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study.
abstract: To evaluate efficacy and tolerability of the combination of clozapine with an antipsychotic long-acting injectable (LAI) in multi-episode patients with schizophrenia or schizoaffective disorder. Efficacy and tolerability were assessed in seventeen patients admitted to a hospital in Paris between January 2010 and June 2015, using a one-year mirror-image design. Number and length of hospitalizations significantly decreased after introducing the combination (2.1 vs 0.8, p=0.004 and 155.4days vs 26.6days, p<0.001 respectively). No major adverse events occurred in terms of increased weight, agranulocytosis, hyperglycemia and/or dyslipidemia. This combination can be beneficial and safe in multi-episode patients.
authors.affiliation: Department of Psychiatry, Service Hospitalo-Universitaire, Centre Hospitalier Sainte-Anne, Paris, France. Electronic address: lama_souaiby@hotmail.com.
authors.forename: Lama
authors.initials: L
authors.lastname: Souaiby
authors.affiliation: Department of Psychiatry, Service Hospitalo-Universitaire, Centre Hospitalier Sainte-Anne, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Paris, France; INSERM, Laboratoire de Physiopathologie des Maladies Psychiatriques, Centre de Psychiatrie et Neurosciences, UMR S894, Paris, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Gauthier
authors.affiliation: Department of Pharmacy, Centre Hospitalier Sainte-Anne, Paris, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Rieu
authors.affiliation: Department of Psychiatry, Service Hospitalo-Universitaire, Centre Hospitalier Sainte-Anne, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Paris, France; INSERM, Laboratoire de Physiopathologie des Maladies Psychiatriques, Centre de Psychiatrie et Neurosciences, UMR S894, Paris, France.
authors.forename: Marie-Odile
authors.initials: MO
authors.lastname: Krebs
authors.affiliation: Department of Pharmacy, Centre Hospitalier Sainte-Anne, Paris, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Advenier-Iakovlev
authors.affiliation: Department of Psychiatry, Service Hospitalo-Universitaire, Centre Hospitalier Sainte-Anne, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Paris, France; INSERM, Laboratoire de Physiopathologie des Maladies Psychiatriques, Centre de Psychiatrie et Neurosciences, UMR S894, Paris, France.
authors.forename: Raphaël
authors.initials: R
authors.lastname: Gaillard
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003024:Clozapine / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D007267:Injections; D007391:International Cooperation; D007902:Length of Stay; D008297:Male; D011618:Psychotic Disorders / Q000188:drug therapy*; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D003024:Clozapine
keywords: Clozapine; Long-acting injectable antipsychotic; Schizophrenia